Prostate rhabdomyosarcoma

Summary

Prostate rhabdomyosarcoma (MONDO:0006389) is a disease. A subtype of prostate sarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	prostate rhabdomyosarcoma
Mondo ID	MONDO:0006389
EFO	EFO:1000498
DOID	DOID:3252
NCIT	C5522
UMLS	C1335518
MedGen	233356
GARD	0024394
Anatomy (UBERON)	UBERON:0002367
Is cancer (heuristic)	no

Also known as: prostate gland rhabdomyosarcoma · prostate gland rhabdomyosarcoma (disease) · prostate rhabdomyosarcoma · rhabdomyosarcoma (disease) of prostate gland · rhabdomyosarcoma of prostate · rhabdomyosarcoma of the prostate

Disease family

This is a subtype of prostate sarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › reproductive system cancer › male reproductive organ cancer › prostate cancer › prostate sarcoma › prostate rhabdomyosarcoma

Related subtypes (3): prostate angiosarcoma, prostate leiomyosarcoma, prostate stromal sarcoma

Subtypes (1): prostate embryonal rhabdomyosarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.